First look: new drug tested for rare autoimmune disease
NCT ID NCT06196905
Summary
This was a very small, early-stage study to gather initial information on a potential new drug called MT-2990 for ANCA-associated vasculitis (AAV), a rare autoimmune disease. It involved only 5 patients with active AAV. The main goal was to explore the drug's safety, how it works in the body, and its initial effects on disease activity and patient symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hiroshima University Hospital
Hiroshima, Hiroshima, 734-8551, Japan
-
Juntendo University Hospital
Bunkyo-ku, Tokyo, 113-8431, Japan
-
Kagawa University Hospital
Kita-gun, Kagawa-ken, 761-0793, Japan
-
Keio University Hospital
Shinjuku-ku, Tokyo, 160-8582, Japan
-
Kyorin University Hospital
Mitaka-shi, Tokyo, 181-8611, Japan
-
NHO Tokyo Medical Center
Meguro-ku, Tokyo, 152-8902, Japan
-
Saitama Medical Center
Kawagoe, Saitama, 350-8550, Japan
-
Saitama Medical University Hospital
Iruma-gun, Saitama, 350-0495, Japan
Conditions
Explore the condition pages connected to this study.